Overview

The marketing authorisation for Prepandrix has been withdrawn at the request of the marketing-authorisation holder. 

български (BG) (776.12 KB - PDF)

View

español (ES) (655.14 KB - PDF)

View

čeština (CS) (735.51 KB - PDF)

View

Deutsch (DE) (680.17 KB - PDF)

View

eesti keel (ET) (653.25 KB - PDF)

View

ελληνικά (EL) (782.77 KB - PDF)

View

français (FR) (682.1 KB - PDF)

View

italiano (IT) (654.6 KB - PDF)

View

latviešu valoda (LV) (750.57 KB - PDF)

View

lietuvių kalba (LT) (705.98 KB - PDF)

View

magyar (HU) (753.62 KB - PDF)

View

Malti (MT) (759.76 KB - PDF)

View

Nederlands (NL) (677.38 KB - PDF)

View

polski (PL) (753.77 KB - PDF)

View

português (PT) (655.51 KB - PDF)

View

română (RO) (705.46 KB - PDF)

View

slovenčina (SK) (760.78 KB - PDF)

View

slovenščina (SL) (744.7 KB - PDF)

View

Suomi (FI) (655.55 KB - PDF)

View

svenska (SV) (677.15 KB - PDF)

View

Product information

български (BG) (2.84 MB - PDF)

View

español (ES) (1.81 MB - PDF)

View

čeština (CS) (2.53 MB - PDF)

View

dansk (DA) (1.85 MB - PDF)

View

Deutsch (DE) (1.85 MB - PDF)

View

eesti keel (ET) (1.79 MB - PDF)

View

ελληνικά (EL) (2.91 MB - PDF)

View

français (FR) (1.85 MB - PDF)

View

hrvatski (HR) (1.87 MB - PDF)

View

íslenska (IS) (1.82 MB - PDF)

View

italiano (IT) (1.84 MB - PDF)

View

latviešu valoda (LV) (2.6 MB - PDF)

View

lietuvių kalba (LT) (1.94 MB - PDF)

View

magyar (HU) (2.51 MB - PDF)

View

Malti (MT) (2.61 MB - PDF)

View

Nederlands (NL) (1.82 MB - PDF)

View

norsk (NO) (1.8 MB - PDF)

View

polski (PL) (2.56 MB - PDF)

View

português (PT) (1.85 MB - PDF)

View

română (RO) (1.97 MB - PDF)

View

slovenčina (SK) (2.56 MB - PDF)

View

slovenščina (SL) (2.48 MB - PDF)

View

Suomi (FI) (1.85 MB - PDF)

View

svenska (SV) (1.81 MB - PDF)

View

Latest procedure affecting product information: IB/0077

20/09/2018

Globe icon

This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

български (BG) (706.57 KB - PDF)

View

español (ES) (599.09 KB - PDF)

View

čeština (CS) (688.89 KB - PDF)

View

dansk (DA) (636.44 KB - PDF)

View

Deutsch (DE) (599.05 KB - PDF)

View

eesti keel (ET) (599.16 KB - PDF)

View

ελληνικά (EL) (692.08 KB - PDF)

View

français (FR) (635.45 KB - PDF)

View

hrvatski (HR) (731.49 KB - PDF)

View

íslenska (IS) (683.46 KB - PDF)

View

italiano (IT) (633.94 KB - PDF)

View

latviešu valoda (LV) (688.77 KB - PDF)

View

lietuvių kalba (LT) (667.71 KB - PDF)

View

magyar (HU) (685.93 KB - PDF)

View

Malti (MT) (691.47 KB - PDF)

View

Nederlands (NL) (598.72 KB - PDF)

View

norsk (NO) (682.3 KB - PDF)

View

polski (PL) (687.41 KB - PDF)

View

português (PT) (635.96 KB - PDF)

View

română (RO) (671.36 KB - PDF)

View

slovenčina (SK) (686.86 KB - PDF)

View

slovenščina (SL) (614.22 KB - PDF)

View

Suomi (FI) (594.07 KB - PDF)

View

svenska (SV) (599.04 KB - PDF)

View

Product details

Name of medicine
Prepandrix
Active substance
A/Indonesia/05/2005 (H5N1) like strain used (PR8-IBCDC-RG2)
International non-proprietary name (INN) or common name
prepandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted)
Therapeutic area (MeSH)
  • Influenza, Human
  • Immunization
  • Disease Outbreaks
Anatomical therapeutic chemical (ATC) code
J07BB02

Pharmacotherapeutic group

Vaccines

Therapeutic indication

Active immunisation against H5N1 subtype of influenza-A virus.

This indication is based on immunogenicity data from healthy subjects from the age of 18 years onwards following administration of two doses of vaccine prepared with H5N1 subtype strains.

Prepandrix should be used in accordance with official guidance.

Authorisation details

EMA product number
EMEA/H/C/000822

Accelerated assessment

This medicine had an accelerated assessment. This means that it is a medicine of major interest for public health, so its timeframe for review was 150 evaluation days rather than 210. For more information, see Accelerated assessment.

Marketing authorisation holder
GlaxoSmithKline Biologicals S.A.

Rue de l'Institut, 89
B-1330 Rixensart
Belgium

Marketing authorisation issued
14/05/2008
Revision
13

Assessment history

This page was last updated on

Share this page